Suppr超能文献

通过心血管磁共振评估发现,再灌注急性心肌梗死后的心脏重塑与血管功能的同步演变有关。

Cardiac remodeling following reperfused acute myocardial infarction is linked to the concomitant evolution of vascular function as assessed by cardiovascular magnetic resonance.

作者信息

Huttin Olivier, Mandry Damien, Eschalier Romain, Zhang Lin, Micard Emilien, Odille Freddy, Beaumont Marine, Fay Renaud, Felblinger Jacques, Camenzind Edoardo, Zannad Faïez, Girerd Nicolas, Marie Pierre Y

机构信息

CHRU-Nancy, Department of Cardiology, Nancy, F-54000, France.

INSERM, UMR-1116, Nancy, F-54000, France.

出版信息

J Cardiovasc Magn Reson. 2017 Jan 4;19(1):2. doi: 10.1186/s12968-016-0314-6.

Abstract

BACKGROUND

Left ventricular (LV) remodeling following acute myocardial infarction (MI) is difficult to predict at an individual level although a possible interfering role of vascular function has yet to be considered to date. This study aimed to determine the extent to which this LV remodeling is influenced by the concomitant evolution of vascular function and LV loading conditions, as assessed by phase-contrast Cardiovascular Magnetic Resonance (CMR) of the ascending aorta.

METHODS

CMR was performed in 121 patients, 2-4 days after reperfusion of a first ST-segment elevation myocardial infarction and 6 months thereafter. LV remodeling was: (i) assessed by the 6-month increase in end-diastolic volume (EDV) and/or ejection fraction (EF) and (ii) correlated with the indexed aortic stroke volume (mL.m), determined by a CMR phase-contrast sequence, along with derived functional vascular parameters (total peripheral vascular resistance (TPVR), total arterial compliance index, effective arterial elastance).

RESULTS

At 6 months, most patients were under angiotensin enzyme converting inhibitors (86%) and beta-blockers (84%) and, on average, all functional vascular parameters were improved whereas blood pressure levels were not. An increase in EDV only (EDV+/EF-) was documented in 17% of patients at 6 months, in EF only (EDV-/EF+) in 31%, in both EDV and EF (EDV+/EF+) in 12% and neither EDV nor EF (EDV-/EF-) in 40%. The increase in EF was mainly and independently linked to a concomitant decline in TPVR (6-month change in mmHg.min.m.L, EDV-/EF-: +1 ± 8, EDV+/EF-: +3 ± 9, EDV-/EF+: -7 ± 6, EDV+/EF+: -15 ± 20, p < 0.001) while the absence of any EF improvement was associated with high persisting rates of abnormally high TPVR at 6 months (EDV-/EF-: 31%, EDV+/EF-: 38%, EDV-/EF+: 5%, EDV+/EF+: 13%, p = 0.007). By contrast, the 6-month increase in EDV was mainly dependent on cardiac as opposed to vascular parameters and particularly on the presence of microvascular obstruction at baseline (EDV-/EF-: 37%, EDV+/EF-: 76%, EDV-/EF+: 38%, EDV+/EF+: 73%, p = 0.003).

CONCLUSION

LV remodeling following reperfused MI is strongly influenced by the variable decrease in systemic vascular resistance under standard care vasodilating medication. The CMR monitoring of vascular resistance may help to tailor these medications for improving vascular resistance and consequently, LV ejection fraction.

TRIAL REGISTRATION

NCT01109225 on ClinicalTrials.gov site (April, 2010).

摘要

背景

急性心肌梗死(MI)后左心室(LV)重构在个体水平上难以预测,尽管血管功能可能的干扰作用至今尚未得到考虑。本研究旨在确定LV重构在多大程度上受血管功能和LV负荷状况的同步演变影响,这通过升主动脉的相位对比心血管磁共振(CMR)进行评估。

方法

对121例患者进行CMR检查,在首次ST段抬高型心肌梗死再灌注后2 - 4天及此后6个月进行。LV重构通过以下方式评估:(i)通过舒张末期容积(EDV)和/或射血分数(EF)在6个月时的增加来评估,以及(ii)与通过CMR相位对比序列确定的指数化主动脉搏出量(mL.m)相关,同时还有推导的功能性血管参数(总外周血管阻力(TPVR)、总动脉顺应性指数、有效动脉弹性)。

结果

在6个月时,大多数患者接受血管紧张素转换酶抑制剂(86%)和β受体阻滞剂(84%)治疗,平均而言,所有功能性血管参数均得到改善,而血压水平未改善。6个月时,17%的患者仅EDV增加(EDV + /EF - ),31%的患者仅EF增加(EDV - /EF + ),12%的患者EDV和EF均增加(EDV + /EF + ),40%的患者EDV和EF均未增加(EDV - /EF - )。EF的增加主要且独立地与TPVR的同步下降相关(6个月时mmHg.min.m.L的变化,EDV - /EF - : +1 ± 8,EDV + /EF - : +3 ± 9,EDV - /EF + : -7 ± 6,EDV + /EF + : -15 ± 20,p < 0.001),而6个月时EF无改善与持续高比例的异常高TPVR相关(EDV - /EF - :31%,EDV + /EF - :38%,EDV - /EF + :5%,EDV + /EF + :13%,p = 0.007)。相比之下,EDV在6个月时的增加主要取决于心脏而非血管参数,特别是取决于基线时微血管阻塞的存在(EDV - /EF - :37%,EDV + /EF - :76%,EDV - /EF + :38%,EDV + /EF + :73%,p = 0.003)。

结论

再灌注心肌梗死后LV重构受标准治疗血管舒张药物作用下全身血管阻力的可变下降强烈影响。CMR对血管阻力的监测可能有助于调整这些药物以改善血管阻力,从而改善LV射血分数。

试验注册

ClinicalTrials.gov网站上的NCT01109225(2010年4月)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d0c/5219670/f14d5f3c8f1a/12968_2016_314_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验